Efficacy and limitations of repurposed drugs and vaccines for COVID-19

Murmu, Nensina; Sarkar, Mrinmoy; Dey, Sananda; Manna, Rahul; Roy, Shreya; Mondal, Tanushree; Halder, Soma; Bhattacharjee, Nandini; Dash, Sandeep K.; Giri, Biplab

doi:10.1016/j.glmedi.2023.100041

Cited by 2 publications

(1 citation statement)

References 211 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical improvement was observed in 68% of patients treated with Remdesivir in a sample of critically ill patients hospitalised for severe COVID-19 [105,106]. A study revealed that remdesivir-treated patients, mostly men in their fifth decade with comorbidities, had a lower mortality risk, reduced incidence of ARDS, and lower ventilator dependency compared with the control group [154].The drug demonstrated effectiveness in mitigating kidney involvement caused by SARS-CoV-2, with no significant adverse effects reported [154,155].…”

Section: Drug Repurposing For Covid-19mentioning

confidence: 99%

Unravelling Insights into the Evolution and Management of SARS-CoV-2

Mushebenge,

Ugbaja,

Mbatha

et al. 2024

BioMedInformatics

View full text Add to dashboard Cite

Worldwide, the COVID-19 pandemic, caused by the brand-new coronavirus SARS-CoV-2, has claimed a sizable number of lives. The virus’ rapid spread and impact on every facet of human existence necessitate a continuous and dynamic examination of its biology and management. Despite this urgency, COVID-19 does not currently have any particular antiviral treatments. As a result, scientists are concentrating on repurposing existing antiviral medications or creating brand-new ones. This comprehensive review seeks to provide an in-depth exploration of our current understanding of SARS-CoV-2, starting with an analysis of its prevalence, pathology, and evolutionary trends. In doing so, the review aims to clarify the complex network of factors that have contributed to the varying case fatality rates observed in different geographic areas. In this work, we explore the complex world of SARS-CoV-2 mutations and their implications for vaccine efficacy and therapeutic interventions. The dynamic viral landscape of the pandemic poses a significant challenge, leading scientists to investigate the genetic foundations of the virus and the mechanisms underlying these genetic alterations. Numerous hypotheses have been proposed as the pandemic has developed, covering various subjects like the selection pressures driving mutation, the possibility of vaccine escape, and the consequences for clinical therapy. Furthermore, this review will shed light on current clinical trials investigating novel medicines and vaccine development, including the promising field of drug repurposing, providing a window into the changing field of treatment approaches. This study provides a comprehensive understanding of the virus by compiling the huge and evolving body of knowledge on SARS-CoV-2, highlighting its complexities and implications for public health, and igniting additional investigation into the control of this unprecedented global health disaster.

show abstract